Procalcitonin in Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

42 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-30

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

hepatocellular carcinom postablation syndrom procalcitonin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with hepatocellular carcinoma

Patients with hepatocellular carcinoma who will undergo locoregional therapy

No interventions assigned to this group

patients with chronic liver disease

patients with chronic liver disease, as a control group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. \- Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
2. \- Fever more than 38C after 48 hours post intervention.

Exclusion Criteria

1. HCC Patients who does not develop fever after intervention.
2. Proven infection elsewhere (e.g. UTI, chest infection..)

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Iman Fawzy Montasser

Lecturer of Tropical medicine ,Faculty of Medicine,Ain Shams university

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hisham K Dabbous, professor

Role: PRINCIPAL_INVESTIGATOR

Tropical medicine department

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tropical medicine department and hepatocellular carcinoma clinic

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HCC and Procalcitonin

Identifier Type: -

Identifier Source: org_study_id